Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: The question which is bugging me..

"7.7 No Interference. From the date hereof through the earlier of the Termination Date or the termination of the Commercialization Agreement, Patriot, Moore and P-Newco shall each avoid and refrain from any and all activity of any kind or nature which may impede, impair, frustrate or otherwise interfere with the activities of TPL in the execution of the commercialization program contemplated by the Commercialization Agreement"

Interesting....Would what Moore is doing going public with his dipute be considered as impeding , imparing, or interfering TPL's licensing activities? He also is no longer involved with reexam activities with the USPTO. Was that his choice? So technically if TPL comes out of this arbritration unscaved, then could not Moore be considered to have breached his contract.?

Perhaps the reason why PTSC is so prudent in all the licensing related activities.

Share
New Message
Please login to post a reply